<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927079</url>
  </required_header>
  <id_info>
    <org_study_id>PI2018_843_0032</org_study_id>
    <nct_id>NCT03927079</nct_id>
  </id_info>
  <brief_title>Predictive Factors of Good Pulmonary Penetration of Antibiotics : AntiBiotics Dosage in Broncho-Alveolar Lavage</brief_title>
  <acronym>ABBA</acronym>
  <official_title>Predictive Factors of Good Pulmonary Penetration of Antibiotics : AntiBiotics Dosage in Broncho-Alveolar Lavage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Respiratory infections are common and sometimes very severe. An insufficient dosage of the
      antibiotic could lead to a treatment failure A correct plasmatic antibiotic concentration is
      not a guarantee of a clinical success as it could not be a reflect of pulmonary
      concentration. The aim of this study is to determinate the predictive factors of pulmonary
      penetration of antibiotics in patients with a beta lactamines failure and who undergoes a
      flexible bronchoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To check if pulmonary concentrations of antibiotic are enough we will measure antibiotic
      concentration in the broncho-alveolar lavage (BAL). This technique which is clinically
      relevant and reliable could determinate the pulmonary diffusion level for antibiotics by
      calculating the ratio between plasmatic and intra-alveolar antibiotic concentration. This
      ratio will be correlated with potential limitation factors of pulmonary diffusion as
      respiratory diseases (COPD, cystic fibrosis, fibrosis…), sepsis, hypoalbuminemia. We have
      chosen to study the beta lactamin antibiotics because they are the most frequently used in
      pneumonia. Moreover, the beta lactamins pulmonary diffusion is likely to be the lowest.
      Finally, for patients with a known pathogen, we will divide this pulmonary concentration with
      minimal inhibitory concentration (MIC). Indeed, in severe pneumonia, to be sure of
      bactericidal activity, a pulmonary concentration of beta lactamines should be always higher
      than 4 to 5 times MIC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2019</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pulmonary diffusion level for beta lactamins</measure>
    <time_frame>on the day of the bronco-alveolar lavage</time_frame>
    <description>pulmonary diffusion level for beta lactamins is determined by ratio between bronchoalveolar concentration and plasmatic concentration of tested antibiotics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>measure of apyrexia duration in days</measure>
    <time_frame>from day of inclusion to 15 days after inclusion</time_frame>
    <description>measure of apyrexia duration in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration in days for regression of the biological inflammatory syndrome</measure>
    <time_frame>from day of inclusion to 15 days after inclusion</time_frame>
    <description>duration in days for regression of the biological inflammatory syndrome (CRP concentration in mg/l divided by 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of length of hospitalisation</measure>
    <time_frame>from day of inclusion to 15 days after inclusion</time_frame>
    <description>measure of length of hospitalisation in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of deaths at 28-day</measure>
    <time_frame>28 days after inclusion</time_frame>
    <description>28-day mortality will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>virus presence in BAL</measure>
    <time_frame>day of bronchoalveolar lavage (BAL)</time_frame>
    <description>virus presence will be detected in bronchoalveolar lavage (BAL)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Antibiotics</condition>
  <condition>Pneumonia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>measure of intra-alveolar antibiotic concentration in µg/ml</intervention_name>
    <description>included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>broncho-alveolar lavage (BAL)</intervention_name>
    <description>included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood test to measure plasmatic antibiotic concentration in µg/ml</intervention_name>
    <description>included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who undergo a flexible bronchoscopic lavage and with a beta lactamines
             treatment as cephalosporin of 3rd generation (CEFTRIAXONE / CEFOTAXIME, CEFTAZIDIME),
             of 4th generation (CEFEPIM), or AMOXICILLIN-CLAVULANIC ACID, or
             PIPERACILLIN-TAZOBACTAM

          -  patient major

          -  informed and signed consent form

        Exclusion Criteria:

          -  patient under chronic dialysis

          -  patient placed under judicial protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire Andrejak, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire Andrejak, Pr</last_name>
    <phone>(33)3 22 08 78 93</phone>
    <email>andrejak.claire@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>claire Andrejak, Pr</last_name>
      <phone>(33)3 22 08 78 93</phone>
      <email>andrejak.claire@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>April 23, 2019</last_update_submitted>
  <last_update_submitted_qc>April 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibiotics</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>broncho-alveolar lavage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

